N/A
N=44
Mechanisms Underlying Local and Systemic Effects of Massage
Muscle Atrophy
Bottom Line
View on ClinicalTrials.gov: NCT04131712 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Percent Change in Myofiber Cross Sectional Area (CSA). — -15.1; -13.4 percent change from baseline
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Massage (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Esther Dupont-Versteegden
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Myofiber Cross Sectional Area (CSA). |
-15.1; -13.4 | — |
| PRIMARY Myofibrillar Protein Synthesis Rate (MyoKsyn). |
1.19; 1.04; 1.07 | — |
| SECONDARY Percent Change in Serum Extracellular Vesicle Number (EV #). |
— | — |
| SECONDARY Percent Change in the Expression of Muscle Rab27b mRNA. |
— | — |
Summary
The purpose of this study is to determine whether massage can attenuate the loss of muscle mass in humans after a short period of disuse.
Eligibility Criteria
Inclusion Criteria
- Men and women 18-30 years of age.
- All races and ethnic backgrounds.
- Non-smoker and generally healthy.
Exclusion Criteria
- Have a current lower extremity musculoskeletal injury or compromised musculoskeletal function that would not allow the safe use of crutches or a brace.
- Previous lower extremity surgeries or injury.
- Activities of daily living require long periods of standing or driving a manual transmission car.
- Body mass index (BMI) under 27.
- Evidence or signs and symptoms of metabolic syndrome or disorder (diagnosis of diabetes or insulin resistance, elevated BP, high fasting blood sugar, abnormal cholesterol or triglyceride levels).
- Thyroid disorder.
- Acute or chronic infections.
- Use of systemic steroids, anabolic steroids, or growth hormone.
- Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding including history of hypo- or hyper-coagulation disorders.
- Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).
- Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance.
- Pregnancy.
Data sourced from ClinicalTrials.gov (NCT04131712). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.